Skip to main content
Premium Trial:

Request an Annual Quote

BioReference Laboratories to Acquire Edge BioServ

NEW YORK (GenomeWeb News) – BioReference Laboratories said today that it will acquire certain assets of Edge Biosystems, a reagents and sequencing services company.

As part of the agreement, BioReference's subsidiary GeneDx will acquire EdgeBio's genetic sequencing service business, Edge BioServ, which provides sequencing services in a CLIA certified laboratory. EdgeBio will retain its products business, a company official told GenomeWeb Daily News.

GeneDx is a clinical diagnostic sequencing laboratory that offers gene panel tests and exome testing services. The acquisition of the Edge BioServ business will include sequencing equipment, and the company said that it would provide the opportunity for GeneDx to expand its services and provide additional testing platforms operating in a CLIA-certified environment.

EdgeBio received CLIA certification last year and currently offers clinical exome sequencing. Additionally, the company has a suite of next-generation sequencing platforms, including Illumina's HiSeq 2000 and MiSeq, as well as Life Technologies' Ion Torrent PGM and Ion Proton.

EdgeBio CEO Dean Gaalaas will assume the role of COO at GeneDx, and the acquisition will also bring a number of R&D personnel from EdgeBio to GeneDx.

"Our GeneDx genetics laboratory is growing rapidly in a very sophisticated and complex area of laboratory medicine and we believe the Edge BioServ acquisition will enable us to have instant expandability for that growth," Marc Grodman, CEO of BioReference Laboratories, said in a statement.

"We have new lines of specialty work being developed, including our upcoming inherited cancers and tumor sequencing programs that we believe will be in great demand. The Edge BioServ acquisition is expected to enable us to seamlessly meet those demands," he added.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.